DexCom Stock Plunge Raises Big Questions – Will This Diabetes Tech Leader Rebound?
Latest News: Earnings Beat Marred by Growth Jitters DexCom’s Q3 2025 earnings (reported Oct. 30) were better than expected, but the celebration was short-lived. The headline numbers were strong – $1.209 B revenue (+22% YoY) and $0.61 adjusted EPS – beating consensus on both investing.com. In fact, demand for DexCom’s G7 continuous glucose monitors (CGMs) drove 20% organic growth globally, with U.S. sales up 21% and international up 18% YoY investing.com. Off the back of this strength, management raised full-year 2025 guidance, now targeting ~$4.63 B revenue (~15% growth) investors.dexcom.com and improved operating margins around 20–21%. However, on the earnings call DexCom’s